Fig. 6

In IBD and CRC patients with CMS4, SETD8 is correlated with poor prognosis and p53 is methylated on lysine 382 in C1Q⁺TPP1⁺ macrophages. A Immunohistochemical analysis of p53 DO7 and p53^K382me1 on colon mucosa of a Crohn’s disease (CD) patient and an Ulcerative colitis (UC) patient at diagnosis and CRC progression. Scale bars, 40 µm. B Immunofluorescence analysis of TPP1, C1Q and p53^K382me1 on colon mucosa of a Crohn’s disease (CD) patient at diagnosis and at CRC progression. Scale bars, 20 µm (left panels). p53^K382me1 positivity percentage of TPP1⁺/C1Q⁺macrophages in colon mucosa of a Crohn’s disease (CD) patient at diagnosis and at CRC progression as shown in left panels. Data are expressed as mean ± SD of three independent experiments (right panel). C Relapse-free survival (RFS) analysis of CD68 and CD163 expression in CRC patients from R2 database (Guinney dataset). Statistical significance was calculated using the log-rank test. D Immunohistochemical analysis of p53^K382me1 , CD68 and CD163 on tumor tissue derived from a p53^WT CRC patient with consensus molecular subtype 4 (CMS4). Scale bars, 40 µm. (E, F) p53^K382me1 positivity percentage of CD68⁺ macrophages (E) or CD163⁺ macrophages (F) in peritumoral, intratumoral tissues and invasive front derived from a p53^WT CRC patient with CMS4 as shown in (D). G Immunofluorescence analysis of TPP1, C1Q and p53^K382me1 on tumor tissue derived from a p53^WT CRC patient with CMS4. Scale bars, 20 µm. H Immunofluorescence analysis of C1QR, CK20 and C1Q in CR-CSphC#8 and THP1 cells. Scale bars, 20 µm. I, J Relapse-free survival (RFS) analysis of C1Q and C1QR expression in CRC patients from R2 database (Guinney dataset). Statistical significance was calculated using the log-rank test. See also Figure S6